World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
60
Citations
12075
World Ranking
3343
National Ranking
139

Overview

Gail V. Matthews is affiliated with the University of New South Wales in Australia. Their research output primarily focuses on the field of Medicine, with notable contributions in Epidemiology, Infectious Diseases, Hepatology, Neurology, and Immunology.

Their work extensively covers several main research topics, including:

  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • HIV, Drug Use, Sexual Risk
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19

Gail V. Matthews has published frequently in the following venues:

  • Journal of Hepatology
  • Clinical Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Viral Hepatitis
  • Open Forum Infectious Diseases

Their recent papers include:

  • Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, 2022, Nature Immunology
  • SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, 2022, EBioMedicine
  • SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants, 2021, PLoS Medicine
  • Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis, 2020, The Lancet. Gastroenterology & hepatology
  • Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial, 2022, The Lancet Respiratory Medicine

Frequent collaborators in their research include:

  • Gregory J. Dore
  • Marianne Martinello
  • Behzad Hajarizadeh
  • Jason Grebely
  • Anthony D. Kelleher

Best Publications

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

    Gillian L. Dean;Simon G. Edwards;Natalie J. Ives;Gail Matthews

  • Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

    Thijis van de Laar;Oliver Pybus;Sylvia Bruisten;David Brown

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection.

    Thijs J W van de Laar;Gail V Matthews;Maria Prins;Mark Danta

  • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

    Jason Grebely;Olav Dalgard;Brian Conway;Evan B Cunningham

  • Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.

    Gail V. Matthews;Mark Bower;Sundhiya Mandalia;Tom Powles

  • Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

    Jason Grebely;Kathy Petoumenos;Margaret Hellard;Margaret Hellard;Gail V. Matthews;Gail V. Matthews

  • An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

    M Nelson;S Portsmouth;J Stebbing;M Atkins

  • Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

    Gail V Matthews;Angeline Bartholomeusz;Stephen Locarnini;Anna Ayres

  • Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

    Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

  • IL28B, HLA-C and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a european cohort: A cross-sectional study

    Vijayaprakash Suppiah;Silvana Gaudieri;Nicola J. Armstrong;Kate S. O'Connor

  • Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

    Mohammed Eslam;Ahmed M Hashem;Reynold Leung;Manuel Romero-Gomez

  • Sexually transmitted hepatitis C infection: the new epidemic in MSM?

    Daniel Bradshaw;Gail Matthews;Mark Danta

  • A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

    Gail V. Matthews;Anchalee Avihingsanon;Sharon R. Lewin;Sharon R. Lewin;Janaki Amin

  • Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection

    Gregory J. Dore;Gregory J. Dore;Margaret Hellard;Margaret Hellard;Gail V. Matthews;Gail V. Matthews;Jason Grebely

  • Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

    Gail V. Matthews;Caroline. A. Sabin;Sundhiya Mandalia;Fiona Lampe

  • SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

    Unknown

  • SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

    Fiona Tea;Alberto Ospina Stella;Anupriya Aggarwal;David Ross Darley;David Ross Darley

  • Characteristics and Treatment Outcomes among HIV-Infected Individuals in the Australian Trial in Acute Hepatitis C

    G. V. Matthews;M. Hellard;P. Haber;B. Yeung

  • Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

    Jason Grebely;Gail V. Matthews;Gail V. Matthews;Margaret Hellard;Margaret Hellard;David Shaw

  • Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

    Chansavath Phetsouphanh;David Darley;Anette Howe;C. Mee Ling Munier

Frequent Co-Authors

Gregory J. Dore
Gregory J. Dore University of New South Wales
Margaret Hellard
Margaret Hellard Burnet Institute
Jason Grebely
Jason Grebely University of New South Wales
Sharon R. Lewin
Sharon R. Lewin University of Melbourne
Andrew R. Lloyd
Andrew R. Lloyd University of New South Wales
John M. Kaldor
John M. Kaldor University of New South Wales
Janaki Amin
Janaki Amin Macquarie University
William D. Rawlinson
William D. Rawlinson University of New South Wales
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Alexander J. Thompson
Alexander J. Thompson Ascension Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees such as nurse practitioner programs can open diverse career paths in healthcare. Many prospective students look for easy nurse practitioner programs to get into as a way to efficiently advance their education and enter the workforce faster.

Specializing further, programs like the best pmhnp programs offer strong clinical placements, which are crucial for hands-on experience in psychiatric mental health nursing. These programs align well with individuals who want to combine immunology knowledge with mental health expertise.

Budget-conscious students often seek out the cheapest psychiatric nurse practitioner programs, which still provide quality education without the financial burden. Balancing cost with program quality is a key consideration in selecting the right educational pathway.

Finally, understanding compensation trends is essential. The dnp salary transparency resource offers insight into salary expectations by location, helping graduates make informed decisions about where to pursue their careers post-degree.

Best Scientists Citing Gail V. Matthews

Trending Scientists

Recently Published Articles